Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-07
2005-06-07
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S381000, C514S449000, C514S467000, C514S469000, C549S432000, C549S434000, C549S462000, C549S491000, C549S497000, C548S250000, C548S252000
Reexamination Certificate
active
06903086
ABSTRACT:
This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I:wherein G1is selected from the group consisting of a, b1and b2,and A and G2are as defined in the specification; or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
REFERENCES:
patent: 5998424 (1999-12-01), Galemmo, Jr. et al.
patent: 6174905 (2001-01-01), Suzuki et al.
patent: 6184242 (2001-02-01), Bley et al.
patent: 2001/0056100 (2001-12-01), Cournoyer et al.
patent: 0974576 (2000-01-01), None
patent: 974576 (2000-01-01), None
patent: WO 00/06550 (1998-07-01), None
patent: WO 01/68591 (2001-09-01), None
Liu et al,PubMed Abstract 12447698,also cited as Oncogene,21/54,8347-50(2002).
Ueno et al, PubMed Abstract 11338374,also cited as Nippon Yakurigaku Zasshi, 117/4,255-61(2001).
Kurashi et al,PubMed Abstract 11338373,also cited as Nippon Yakurigaku Zasshi, 117/4,248-54(2001).
Nishio et al, PubMed Abstract 2514128,also cited as Nippon Yakurigaku Zasshi,94/6,351-61(1989).
Vapaatalo et al,PubMed Abstract 212650,also cited as Med. Biol.,56/4,163-83(1978).
Bley, et al., “The role of IP prostanoid receptors in inflammatory pain”,Trends in Pharmacological Sciences, Apr. 1998, pp. 141-147,19 (4), Elsevier Science Ltd.
Smith, et al., “Characterization of prostanoid receptor-evoked responses in rat sensory neurons,”British Journal of Pharmacology, 1998, pp. 513-523, 124(3), Stockton Press.
Murata, et al., “Altered pain perception and inflammatory response in mice lacking prostacyclin receptor,”Nature, 1997, pp. 678-682, 388(6643), Macmillan Magazines Ltd.
Anderson, et al., “Pharmacology of Lower Urinary Tract Smooth Muscles and Penile Erectile Tissues,”Pharmacological Reviews, 1993, pp. 253-308, 45(3).
Coleman, et al., “VIII. International Union of Pharmacology. Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes”,Pharmacological Reviews, 1994, pp. 205-229, 46(2).
Tsubaki, Kazunori, “A Novel Pyridazinone Derivative as a Nonprostanoid PGI2Agonist”Pergamon, Bioorganic & Medicinal Chemistry Letters, (2000), pp. 2787-2790, vol. 10.
Lopez-Tapia Francisco Javier
Nitzan Dov
O'Yang Counde
Hall Robert C.
Patel Sudhaker B.
Raymond Richard L.
SYNTEX (U.S.A.) LLC
LandOfFree
Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3459250